Movers: Columbia Laboratories, Neurometrix, Cynosure, Receptos, Bristol-Myers Print
Latest News
Tuesday, 28 October 2014 14:32

U.S. stocks climbed in afternoon trading on Tuesday, following stronger-than-expected earnings and an upbeat consumer confidence reading.

Helping the day's upbeat tone, U.S. consumer confidence rose in October to its highest since October 2007. The data overshadowed a separate report showing new orders for capital goods by U.S. businesses fell the most in eight months in September.

Columbia Laboratories Inc.(NASDAQ:CBRX) Q3 results: Revenues: $11.5M (+62.0%); COGS: $5.1M (+59.4%); R&D Expense: $0.2M (+100.0%); SG&A: $2.6M (+52.9%); Operating Income: $3.5M (+169.2%); Net Income: $3.7M (+117.6%); EPS: $0.34 (+209.1%); Quick Assets: $16.4M (-20.8%).

Neurometrix Inc(NASDAQ:NURO) Q3 results: Revenues: $1.4M (+7.7%); Gross Profit: $0.8M (+14.3%); R&D Expense: $1M (+42.9%); SG&A: $1.8M (+12.5%); Operating Loss: ($2M) (-25.0%); Net Loss: ($1.5M) (-114.3%); Loss Per Share: ($0.19) (+26.9%); Quick Assets: $11.7M (+27.2%).

Cynosure, Inc.(NASDAQ:CYNO) Q3 results: Revenues: $71.5M (+17.8%); COGS: $31.2M (+17.3%); R&D Expense: $5.7M (+14.0%); SG&A: $28.6M (-5.0%); Operating Income: $5.3M (+478.6%); Net Income: $3.1M (+338.5%); EPS: $0.14 (+333.3%); Quick Assets: $53.8M (-42.6%).

Receptos (NASDAQ:RCPT) is up 33% premarket on modest volume in response to yesterday's announcement of positive Phase 2 results for RPC1063 in ulcerative colitis.

Bristol-Myers Squibb Co(NYSE:BMY) enters into an agreement with privately-held Austrian biotech F-star Alpha Ltd. that gives it the exclusive right to acquire the company and its lead asset, FS102, a HER2-targeted therapy for the treatment of breast and gastric cancer. Under the terms of the agreement, BMY will make aggregate payments of $50M consisting of an option fee for the right to acquire F-star Alpha, payment for certain rights and licenses from F-star and a clinical milestone payment upon the initiation of the Phase 1 clinical trial. BMY will conduct and fund the development of FS102 during the option period. Total aggregate consideration may reach $475M.

BiomedReports is not paid or compensated by newswires to disseminate or report news and
developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and

Error. Page cannot be displayed. Please contact your service provider for more details. (6)

investor relation services from various entities and
firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus